Skip to main content

Memorial Tributes Volume 25 (2023) / Chapter Skim
Currently Skimming:

JOHN C. MARTIN
Pages 326-331

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 327...
... WHITLEY SUBMITTED BY THE NAE HOME SECRETARY J OHN CHARLES MARTIN, a chemist, long-time chief executive officer of the biopharmaceutical company Gilead Sciences Inc., and more recently a philanthropist dedicated to addressing health disparities in communities around the world, died March 30, 2021, at the age of 69. John was born in Easton, Pennsylvania, on May 7, 1951.
From page 328...
... This drug and its prodrug remain cornerstones in the management of cytomegalovirus infections. John joined Bristol Myers in 1984 to lead its antiviral and antiinfective research programs in Syracuse, New York, where he directed the development and eventual licensure of two dideoxynucleoside antivirals to treat HIV/AIDS -- didanosine and stavudine.
From page 329...
... A few years later, following John's vision, the company gained regulatory approval for the first HIV medication indicated to prevent transmission of the infection, an approach known as preexposure prophylaxis, or PrEP, for people at risk for HIV infection. To continually advance patient care, John's directive was that "we must continue to innovate to make obsolete our own products," where each innovation improved on the prior advance.
From page 330...
... John's commitment to addressing health disparities was fueled by a deep understanding based on first-hand observations. He traveled to regions of the world most ­ impacted -- ­ sub-Saharan Africa, Southeast Asia, and Latin America -- and met with healthcare providers, public policy experts, and people doing the work in these regions to develop a better understanding of the barriers individuals faced daily.
From page 331...
... . He served on the boards of Golden Gate University, University of Southern California, University of Chicago, University of California School of Global Health, Scripps Research Institute, Sarepta Therapeutics, Leyden Labs, and Kronos Bio.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.